Artemisinin-based combination therapy for ... - The Cochrane Library

(... Continued)
Study or subgroup AL6 AQ+SP Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Dorsey 2006 UGA 2/100 8/105 0.26 [ 0.06, 1.21 ]
Subtotal (95% CI) 761 775 0.46 [ 0.21, 1.01 ]
Total events: 8 (AL6), 19 (AQ+SP)
Heterogeneity: Chi 2 = 5.94, df = 3 (P = 0.11); I 2 =50%
Test for overall effect: Z = 1.94 (P = 0.052)
0.001 0.01 0.1 1 10 100 1000
Favours AL6 Favours AQ+SP
Analysis 11.6. Comparison 11 Artemether-lumefantrine vs Amodiaquine plus sulfadoxine-pyrimethamine,
Outcome 6 Gametocyte development (in those negative at baseline).
Review: Artemisinin-based combination therapy for treating uncomplicated malaria
Comparison: 11 Artemether-lumefantrine vs Amodiaquine plus sulfadoxine-pyrimethamine
Outcome: 6 Gametocyte development (in those negative at baseline)
Study or subgroup AL6 AQ+SP Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Zongo 2007 BFA 3/188 10/183 100.0 % 0.29 [ 0.08, 1.04 ]
Total (95% CI) 188 183 100.0 % 0.29 [ 0.08, 1.04 ]
Total events: 3 (AL6), 10 (AQ+SP)
Heterogeneity: not applicable
Test for overall effect: Z = 1.89 (P = 0.058)
0.05 0.2 1 5 20
Favours AL6 Favours AQ+SP
Artemisinin-based combination therapy for treating uncomplicated malaria (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
187